SLDB
Price
$6.71
Change
-$0.16 (-2.33%)
Updated
Oct 12 closing price
Capitalization
780.6M
29 days until earnings call
Intraday BUY SELL Signals
STOK
Price
$24.15
Change
-$0.59 (-2.38%)
Updated
Oct 12 closing price
Capitalization
1.65B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SLDB vs STOK

SLDB vs STOK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SLDB vs. STOK commentary
Oct 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLDB is a Buy and STOK is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
SLDB vs STOK: Fundamental Ratings
SLDB
STOK
OUTLOOK RATING
1..100
7959
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6580
P/E GROWTH RATING
1..100
33
SEASONALITY SCORE
1..100
2835

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for STOK (84) in the null industry. This means that SLDB’s stock grew somewhat faster than STOK’s over the last 12 months.

STOK's Profit vs Risk Rating (98) in the null industry is in the same range as SLDB (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to SLDB’s over the last 12 months.

STOK's SMR Rating (98) in the null industry is in the same range as SLDB (98) in the Biotechnology industry. This means that STOK’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's Price Growth Rating (65) in the Biotechnology industry is in the same range as STOK (80) in the null industry. This means that SLDB’s stock grew similarly to STOK’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as STOK (3) in the null industry. This means that SLDB’s stock grew similarly to STOK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLDBSTOK
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 25 days ago
81%
Bullish Trend 12 days ago
89%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
COMPARISON
Comparison
Oct 13, 2026
Stock price -- (SLDB: $6.71 vs. STOK: $24.15)
Brand notoriety: SLDB and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLDB: 55% vs. STOK: 46%
Market capitalization -- SLDB: $780.6M vs. STOK: $1.65B
SLDB [@Biotechnology] is valued at $780.6M. STOK’s [@Biotechnology] market capitalization is $1.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLDB’s FA Score shows that 2 FA rating(s) are green while STOK’s FA Score has 1 green FA rating(s).

  • SLDB’s FA Score: 2 green, 3 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, SLDB is a better buy in the long-term than STOK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLDB’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • SLDB’s TA Score: 4 bullish, 6 bearish.
  • STOK’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, STOK is a better buy in the short-term than SLDB.

Price Growth

SLDB (@Biotechnology) experienced а -4.96% price change this week, while STOK (@Biotechnology) price change was -4.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.09%. For the same industry, the average monthly price growth was -11.53%, and the average quarterly price growth was -11.77%.

Reported Earning Dates

SLDB is expected to report earnings on Nov 11, 2026.

STOK is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-5.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
SLDB
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LW50.182.31
+4.83%
Lamb Weston Holdings
SYK282.605.27
+1.90%
Stryker Corp
CTBI74.630.47
+0.63%
Community Trust Bancorp
EFTY15.02N/A
N/A
Etoiles Capital Group Co Ltd
GAIA1.26-0.07
-5.26%
Gaia

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-2.33%
EDIT - SLDB
59%
Loosely correlated
-5.17%
CRBU - SLDB
56%
Loosely correlated
+7.97%
RCKT - SLDB
54%
Loosely correlated
-3.12%
IMTX - SLDB
53%
Loosely correlated
-2.96%
BEAM - SLDB
53%
Loosely correlated
-2.22%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with RCKT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-2.38%
RCKT - STOK
54%
Loosely correlated
-3.12%
TSHA - STOK
50%
Loosely correlated
-7.80%
SLDB - STOK
49%
Loosely correlated
-2.33%
QTTB - STOK
49%
Loosely correlated
+4.80%
CLDX - STOK
45%
Loosely correlated
-1.54%
More